Press Releases

MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women

Download PDF

Clinical Study will be Completed and its Results Announced in the Second Half of 2018

CEDAR KNOLLS, N.J., Dec. 6, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), has entered into a research agreement with the University of California, Berkeley's Department of Nutritional Sciences & Toxicology.  The study will look into the effects of Fortetropin® on increasing the fractional rate of skeletal muscle protein synthesis in men and women between 60 and 75 years old.  Fortetropin®, owned by MYOS RENS, a bionutrition company, is a natural food product that helps build lean muscle in conjunction with resistance training.  The Principal Investigator for this clinical study will be William J. Evans, PhD, Adjunct Professor of Human Nutrition at the Department of Nutritional Sciences & Toxicology at the University of California, Berkeley campus.  Professor Evans, a leading authority in muscle health research, will coordinate the activities of a multi-disciplinary team of scientists and physicians. 

Fortetropin® is the Company's proprietary all-natural food ingredient clinically shown to increase muscle size, lean body mass and strength as part of resistance training.  Fortetropin® is made from fertilized chicken egg yolks using a proprietary process that retains the biological integrity and bioactivity of the product.  In an animal study, Fortetropin® was shown to up-regulate muscle building and down-regulate muscle destruction pathways.

In this randomized, double-blind, placebo-controlled clinical study, 20 subjects, men and women 60 – 75 years of age, will take either Fortetropin® or placebo for 21 days along with daily doses of a heavy water tracer.  After 21 days, a microbiopsy will be collected from each subject to determine the fractional rate of muscle protein synthesis.  MYOS anticipates the clinical study will be completed and its results announced in the second half of 2018.

"This study represents part of MYOS' strategy to leverage cutting edge technologies that have been developed by pioneers in the field of muscle health to better understand the potential benefits of Fortetropin® across many broad areas.  Favorable results from this study may help to support individuals who want to maintain optimal muscle health as they age," said Joseph Mannello, CEO of MYOS. 

Professor Evans said, "My colleagues and I are excited about this research.  Maintaining good muscle health is vital to enjoying a good quality of life as we age.  It is well understood that people lose muscle as they age.  Scientists believe that reduced rates of muscle protein synthesis play a primary role in age-related muscle loss.  Positive results from this clinical study may represent an exciting advance in addressing age-related muscle loss in the elderly population."

About MYOS RENS Technology Inc. 
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, the world's first clinically-demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth. Fortetropin® is a fertilized egg yolk based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin® has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin® has the potential to redefine existing standards of physical health and wellness. For more information, please visit

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr® products, the success of our research and development, including the clinical study described above, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700

View original content with multimedia: